Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2 EUR
47.25 M EUR
118.97 M EUR
18.48 M
About Ligand Pharmaceuticals Incorporated
Sector
CEO
Todd C. Davis
Headquarters
Jupiter
Website
Founded
1987
FIGI
BBG000BMKKW6
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange LIGAND PHARMAC.NEW DL-001 stocks are traded under the ticker LGDN.
We've gathered analysts' opinions on LIGAND PHARMAC.NEW DL-001 future price: according to them, LGDN price has a max estimate of 154.56 EUR and a min estimate of 120.75 EUR. Watch LGDN chart and read a more detailed LIGAND PHARMAC.NEW DL-001 stock forecast: see what analysts think of LIGAND PHARMAC.NEW DL-001 and suggest that you do with its stocks.
LGDN reached its all-time high on Oct 1, 2018 with the price of 176 EUR, and its all-time low was 0.781131 EUR and was reached on Nov 22, 2010. View more price dynamics on LGDN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track LIGAND PHARMAC.NEW DL-001 financials in yearly and quarterly reports right on TradingView.
LIGAND PHARMAC.NEW DL-001 is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
LGDN earnings for the last quarter are 1.65 EUR per share, whereas the estimation was 1.21 EUR resulting in a 36.59% surprise. The estimated earnings for the next quarter are 1.15 EUR per share. See more details about LIGAND PHARMAC.NEW DL-001 earnings.
LIGAND PHARMAC.NEW DL-001 revenue for the last quarter amounts to 46.53 M EUR, despite the estimated figure of 36.46 M EUR. In the next quarter, revenue is expected to reach 37.70 M EUR.
LGDN net income for the last quarter is −6.44 M EUR, while the quarter before that showed −48.46 M EUR of net income which accounts for 86.71% change. Track more LIGAND PHARMAC.NEW DL-001 financial stats to get the full picture.
No, LGDN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 10, 2025, the company has 58.00 employees. See our rating of the largest employees — is LIGAND PHARMAC.NEW DL-001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LIGAND PHARMAC.NEW DL-001 EBITDA is 49.91 M EUR, and current EBITDA margin is 35.97%. See more stats in LIGAND PHARMAC.NEW DL-001 financial statements.
Like other stocks, LGDN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LIGAND PHARMAC.NEW DL-001 stock right from TradingView charts — choose your broker and connect to your account.